Am J Transplant, Volume 17, Suppl 3 Archives - Page 52 of 181 - ATC Abstracts

2017 American Transplant Congress
Bortezomib for Late Antibody-Mediated Rejection After Renal Transplantation: A Single Center Experience of 22 Cases.
J. Choi, J. Jung, S. Chun, S. Shin, Y. Kim, D. Han.
Department of General Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Despite of tradifional treatments for AMR, such as plasapheresis, ingravenous immunoglobulin, and rituximab, current treatment for antibody-mediated rejection(AMR) after renal transplantation is insufficient. Recently, Bortezomib…
2017 American Transplant Congress
Outcomes of Active Screening for Carbapenem-Resistant Enterobacteriaceae among Liver Transplant Recipients.
T. Bias,¹ G. Malat,¹ D. Lee,² S. Talluri,² K. Ranganna,² S. Epstein,² V. Patel,² S. Guy.³
¹Department of Pharmacy, Drexel University College of Medicine, Philadelphia, PA; ²Department of Medicine, Drexel University College of Medicine, Philadelphia, PA; ³Department of Surgery, Drexel University College of Medicine, Philadelphia, PA
Background: Preventive strategies to combat the transmission of Carbapenem-Resistant Enterobacteriaceae (CRE) include the use of active screening for CRE colonization; however, this approach is not…
2017 American Transplant Congress
Prevalence of Cutaneous Disease in Solid Organ Transplant Recipients: A 5-Year Study from a Medical -Surgical Transplant Dermatology Center.
R. Allawh, A. Weiffenbach, K. Nadhan, M. Abdelmalek, C. Cusack, C. Chung.
Dermatology, Drexel University College of Medicine, Philadelphia, PA
Background: Solid organ transplant recipients (OTR) on chronic immunosuppression exhibit heightened risk of developing a myriad of cutaneous manifestations compared to non-transplant patients, including cutaneous…
2017 American Transplant Congress
Gene Editing of Keap1/Nrf2 in Human T Cells Using CRISPR-Cas9 to Improve Outcome from Ischemia Reperfusion Injury and Other T Cell Mediated Diseases.
S. Noel,¹ S. Lee,¹ M. Sadasivam,² A. Hamad,² H. Rabb.¹
¹Department of Medicine, Johns Hopkins University, Baltimore, MD; ²Department of Pathology, Johns Hopkins University, Baltimore, MD
Background: T lymphocytes are important mediators of ischemia reperfusion injury (IRI) during organ transplantation. Using genetically engineered mice, we demonstrated that augmentation of Nrf2 dependent…
2017 American Transplant Congress
Alternations in Amplitude of Low Frequency Fluctuation in Renal Allograft Recipients That Received Tacrolimus or Sirolimus: An fMRI Study.
J. Wen,¹ X. Ni,¹ L. Wu,² G. Zheng,² L. Zhang,² J. Chen.¹
¹National Clinical Research Center of Kidney Diseases, Jinling Hospital, Medical School of Nanjing University, Nanjing, China; ²Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, China
Objective The side-effects of resting tremor was common in renal transplant receipts receive tacrolimus. But the mechanism of this side-effect was unknown. This study want…
2017 American Transplant Congress
Immunosuppressant Costs for Medicare Part D and Kidney Transplant Recipients Since the Introduction of Generic Formulations in an Incident Kidney Transplant Population.
M. Helmuth,¹ M. Turenne,¹ J. Park,² Q. Liu,¹ M. Oguntimein,³ S. Dutcher,³ R. Balkrishnan,⁴ J. Zee,¹ A. Smith,¹ A. Leichtman.¹
¹Arbor Research Collaborative for Health, Ann Arbor, MI; ²U of Michigan, Ann Arbor, MI; ³Food and Drug Administration, Silver Spring, MD; ⁴U of Virginia, Charlottesville, VA
Background: Substitution of generics (GEN) for brand name (BN) immunosuppressants (IS) has increased in kidney transplant recipients (KTR) since the introduction of GEN mycophenolate mofetil…
2017 American Transplant Congress
Understanding the Role of Induction Agents in Older versus Younger Kidney Transplant Recipients.
Q. Huang, F. Ammary, M. McAdams-DeMarco, D. Segev.
Johns Hopkins University, Baltimore, MD
Background: There has been an increase in the number of older (over 65) KT recipients. Aging-related changes such as differences in immune senescence may influence…
2017 American Transplant Congress
Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients.
M. Marron-Wojewodzki,¹ I. Szwarc,¹ C. Rene,² J.-F. Eliaou,² G. Mourad,¹ M. Le Quintrec.^1,3
¹Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France; ²Departement of Immunology, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France; ³Inserm U1183, IRMB, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France
Background. In kidney transplantation, de novo donor specific antibodies (dnDSA) are associated with antibody-mediated rejection (AMR) and graft failure. After dnDSA development, 24% of the…
2017 American Transplant Congress
Endoscopic Therapy of Bile Duct Strictures After Liver Transplant.
H. Woller, P. Mantry, A. Mejia, S. Cheng, C. Fasola.
Gastroenterolgy and Hepatology, Methodist Dallas Medical Center, Dallas, TX
Background and Aims: Common Bile Duct Strictures (CBDS) are a significant source of morbidity after liver transplantation (LT) We report our outcomes of endoscopic treatment…
2017 American Transplant Congress
Extending the Limit for Living Donor Liver Transplantation: Similar Outcomes After Left vs. Right Lobe Graft, a Propensity Score Analysis.
T. Wong, K. Ng, J. Fung, K. Chok, A. Chan, C. Lo.
Surgery, The University of Hong Kong, Hong Kong, Hong Kong
BackgroundThis study aimed to investigate the impact of graft selection (left vs. right lobe) in LDLT.MethodThis was a retrospective study that included all patients who…